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ABSTRACT 
Objective: The aim of the present study was to evaluate the in vivo behaviour of budesonide microspheres for colon targeted delivery. 
Methods: In vivo therapeutic effect was evaluated using trinitrobenzene sulfonic acid (TNBS) induced colitis in rats. The therapeutic effect was 
assessed by determining the damage score, clinical activity score, colon/body weight(C/B) ratio and myeloperoxidase (MPO) activity measurement. 
The data were compared with standard drug 5-aminosalicylic acid (5-ASA). The targeting efficiency of the formulation was assessed by X-ray 
studies on the rabbit. 
Results: The study showed that oral administration of budesonide microspheres exerted an affirmative impact on the colonic ulcer healing by 
decreasing the area of ulceration, reducing the mass of colon by improving the symptoms of colitis. MPO activity decreased significantly after oral 
administration of microspheres. Histopathological studies carried out also confirmed the result. The X-ray studies revealed that the formulations 
were able to target the colon.  
Conclusion: The in vivo study confirmed the ability of budesonide microspheres in targeting the colonic region. 
Keywords: Budesonide, Colitis, Targeted delivery, Myeloperoxidase, Ulceration, Clinical activity score 
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INTRODUCTION 
Targeted drug delivery into the colon is highly desirable for local 
treatment of a variety of bowel diseases such as ulcerative colitis, 
Crohn’s disease, amoebiasis, colon cancer and systemic delivery of 
proteins and peptide drugs [1, 2]. The pathogenesis likely involves 
genetic, environmental and immunological factors [3]. Ulcerative 
colitis is a type of inflammatory bowel disease that affects the lining 
of the large intestine, colon and rectum. It can be treated more 
effectively by local delivery of anti-inflammatory drugs such as 5-
aminosalicylicacid (5-ASA) and corticosteroids to the colon. Newer 
corticosteroids with high local activity and low systemic side effects 
are the drug of choice for the treatment of inflammatory bowel 
disease [4]. Budesonide is a locally acting corticosteroid and has the 
highest affinity for glucocorticoid receptor [5]. It is approved as a 
standard drug for the localized treatment of inflammatory bowel 
disorder due to negligible oral bioavailability, rapid clearance and no 
active metabolites [6]. In the present study, the drug budesonide 
was formulated into microspheres and its targeting efficiency was 
evaluated in vivo. 
MATERIALS AND METHODS 
Materials 
Budesonide was purchased from Astra Zeneca, UK. Chitosan was 
received as a gift sample from Central Institute of Fisheries 
Technology, Kochi. Trinitrobenzenesulfonic acid (TNBS) was 
purchased from Sigma Chemicals, USA. 
5-Aminosalicylic acid and barium sulphate were procured from 
Apollo Pharmaceuticals, Mumbai and Eudragit-S 100 was obtained 
from Degussa India Pvt Ltd, Mumbai. All other reagents and 
chemicals used were of analytical grade. 
Methods 
Preparation and characterization of microspheres  
Chitosan microspheres were prepared using ionotropic gelation 
process with counter polyanion tripolyphosphate (TPP) [7, 8]. A 2 
factor 3 levels full factorial design was used for the formulation of 
microspheres. The amount of polymer chitosan (2, 4 and 6 %v/v) 
and cross-linking agent TPP (5, 7.5 and 10%v/v) were selected as 
independent variables and the amount of drug release, particle size 
and entrapment efficiency were selected as dependent variables. 
Chitosan was dissolved by stirring for 60 min in a 2%v/v acetic acid 
solution to obtain a transparent and homogeneous solution. The 
drug budesonide (9 mg) was then dispersed in chitosan solution. 
Microspheres were formed by dropping 10 ml of this bubble free 
dispersion of chitosan through 22# disposable syringe into gently 
agitated (magnetic stirrer) 40 ml of TPP solution. The formed 
microspheres were separated after 2 h by filtration, washed 
thoroughly with reverse osmosis (RO) water and then air dried. 
The prepared microspheres were coated with eudragit S-100 
polymer by solvent evaporation method [9]. 50 mg of microspheres 
were dispersed in 10 ml of coating solution prepared by dissolving 
500 mg of eudragit S-100 in ethanol: acetone (2:1). This organic 
phase was poured in to 70 ml of light liquid paraffin containing 1% 
w/v span 80. The system was agitated for a period of 3 h with a 
speed of 1000 rpm. The coated microspheres were filtered after the 
evaporation of the solvent, washed with n-hexane, and dried. 
Prepared microspheres were characterized for micrometric 
properties, entrapment efficiency and in vitro drug release study 
[10]. The formulation which exhibited good entrapment efficiency 
and drug release behaviour was selected for in vivo study. 
In vivo study 
Before commencement of the experimentation on animals, the 
experimental protocol was subjected to the scrutiny of the 
Institutional Animal Ethical Committee, and it was approved by the 
committee. Institutional Animal Ethical Committee, Govt Medical 
college, Kozhikode has given consent for conducting the animal 
experiment–No IAEC/08/2013 dtd 12/03/2013. 
Induction of experimental colitis 
Colitis was induced using trinitrobenzene sulfonic acid (TNBS) [11]. 
Male albino rats (average weight-200-300 g, 12-15 w, n=6/group) 
were distributed into six different groups. The animals fasted for 48 
h before experimentation and allowed food and water ad libitum 
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after the administration of TNBS. To induce inflammation, all groups 
except healthy control group were treated by the following 
procedure. After light anaesthesia with ether, the rats were 
catheterized 8 cm intra-rectally, and 500μl of TNBS in ethanol was 
applied (dose was 150 mg/kg body weight of TNBS in ethanol 50% 
solution) into the colon via rubber cannula. Animals were then 
maintained in a vertical position for 30 s, and returned to their 
cages. For 3 d the rats were housed without treatment, to maintain 
the development of full inflammatory bowel disease model. 
Treatment groups 
Rats were randomized into six different groups, each consisting of 
six animals. a. healthy control group, b. colitis control group, c. group 
receiving a suspension of drug (budesonide), d. group receiving a 
suspension of standard drug (5-ASA), e. group receiving a 
suspension of formulated microspheres and f. group receiving 
polymer (chitosan) suspension. The suspension was prepared using 
normal saline in all cases. The animals received treatment orally 
once daily for 7 continuous days. Healthy control and colitis control 
group received only saline. Oral dose for rat was calculated from the 
dose of human [12]. Animals were sacrificed with carbon dioxide 24 
h after the last drug administration. A segment of colon 8 cm long 
was excised and evaluated. 
Determination of colon/body weight ratio (C/B ratio) 
The C/B weight ratio was calculated as an index of colonic tissue 
oedema [13]. The rats were killed, then the abdomen was opened, 
and the distal colon was rapidly excised and opened longitudinally 
along the mesenteric edge. The distal colon specimen was rinsed 
with isotonic saline. An 8 cm segment showing gross pathological 
changes was weighed for determining C/B mass ratio. 
Clinical activity score 
Colitis activity was quantified with a clinical score assessing weight 
loss, stool consistency and rectal bleeding [14]. No weight loss was 
counted as 0 point, 1to 5% as 1 point, 5 to 10% as 2 points, 10 to 20 
% as 3 points and>20% as 4 points. For stool consistency, 0 point 
was given for well-formed pellets, 2 points for pasty and semi-
formed stools that did not stick to the anus, and 4 points were given 
for liquid stools that stick to the anus. Bleeding was scored as 0 point 
for no blood, 2 points for positive finding, and 4 points for gross 
bleeding. The mean of these scores forms the clinical score ranging 
from 0 (healthy) to 4 ( the maximal activity of colitis). 
Assessment of macroscopic ulceration (damage score) 
Gross mucosal damage [11] was scored on a 0-5 grade scale by two 
independent observers who were blinded to the treatment. Damage 
was scored as follows:  
Score 0 no damage 
Score 1 localized hyperemia with no ulceration 
Score 2 linear ulceration with no significant inflammation 
Score 3 linear ulcers with inflammation at one site 
Score 4 two or more sites of ulceration and/or inflammation 
Score 5 two or more sites of ulceration and inflammation or one major 
sites of inflammation and ulceration>1 cm along the length of colon 
Measurement of myeloperoxidase (MPO) activity 
The distal colon specimen (200 mg) was minced in a beaker 
containing 1 ml of hexadecyl trimethyl ammonium bromide (HTAB) 
buffer (0.5% HTAB in 50 mM phosphate buffer, pH 6.0) on ice, 
transferred to a test tube and homogenized (three times for 30 s 
each on ice). After homogenization, the homogenizer was rinsed 
twice with 1 ml of HTAB. The pooled homogenate and washes were 
sonicated for 10 s, freeze-thawed three times, and centrifuged at 
10,000 rpm for 15 min. The supernatant was assayed 
spectrophotometrically for MPO activity [15]. 0.1 ml of supernatant 
was combined with 2.9 ml of 50 mM phosphate buffer (pH 6.0) 
containing 0.167 mg/ml O-dianisidine hydrochloride and 0.0005% 
hydrogen peroxide. The change in absorbance at 460 nm was 
measured. One unit of MPO activity is defined as the amount which 
degrades 1 µmol of the peroxide per min at 25 ℃.  
Histopathological study 
Tissue samples were excised from each colon and maintained in 
10% formaldehyde for histopathological studies [16]. Specimens 
were fixed in 10% buffered formalin solution embedded in paraffin, 
stained with haematoxylin and eosin and then subjected to 
histopathological studies. Microscopic evaluation was performed by 
a pathologist unaware of the study design. 
Determination of in vivo targeting efficiency 
This study was carried out to check the in vivo targeting efficiency of 
the formulation [17, 18]. Rabbits were selected as an animal model 
for evaluating the colon-specific delivery. Roentgenography study, a 
comparatively safer technique was carried out in healthy male 
albino rabbits. The behaviour of budesonide microspheres in rabbit 
was observed using a radiographic imaging technique. It involves 
the use of radio-opaque marker barium sulphate, incorporated in 
the formulation to determine the position of microspheres. Healthy 
rabbits fasted overnight and on the next day morning microspheres 
enclosed in a capsule shell was administered followed by giving 25 
ml of water. At different time intervals, X-ray images were taken 
under the supervision of a radiologist. 
In vivo drug release study 
A capsule containing microspheres having 9 mg of drug was given to 
24h fasted rabbit. Blood samples (1 ml) were taken serially from the 
ear vein of the animals after 0, 2, 6, 8, and 24th
Statistical analysis  
 h of drug 
administration. The plasma was separated by centrifugation for 3 
min at 13,000 rpm. The protein was extracted by adding 1 ml of 
dichloromethane to 1 ml plasma. The organic phase was taken in a 
test tube and evaporated. The residue was dissolved in 2 ml of 
mobile phase consisting of a water/ethanol mixture (57/43 by 
volume). The samples were injected into the high-performance 
liquid chromatography system (HPLC). N-Propyl-p-hydroxy benzoic 
acid-methanol solution was used as an internal standard. The HPLC 
system was equipped with a UV detector at 246 nm in a reverse 
phase column [19]. Presence of drug in the faecal content of rabbit 
was analysed by UV spectrophotometry [20]. 
Results were expressed in mean±SD. Data obtained were subjected 
to one-way analysis of variance (ANOVA) followed by Tukey-Kramer 
multiple comparison tests using GraphpadInstat software. 
RESULTS AND DISCUSSION 
Prepared microspheres were characterized for micrometric 
properties, entrapment efficiency and in vitro drug release study. 
The formulation exhibited good flow behaviour and had good 
entrapment efficiency. The microspheres successfully retarded drug 
release until it entered the colon [10]. 
In vivo results 
The comparison of the therapeutic effect of budesonide 
microspheres and its suspension with the standard drug on C/B 
mass ratio, clinical activity score, body mass change, macroscopic 
damage score and MPO activity in TNBS induced colitis are shown in 
tables (1, 2, 3, 4 and 5). 
Colon/Body mass ratio (C/B mass ratio) 
 
Table 1: Data of C/B mass ratio in control and treatment groups 
after 7 d treatment 
Groups C/B mass ratio (mg/g) 
Healthy Control 2.2±0.82 
Colitis control  9.6±0.33*** 
Budesonide Suspension 6.2±0.26*** 
Standard drug (5-ASA) 6.4±0.18*** 
Budesonide microspheres  5.8±0.14*** $$ 
Polymer suspension 9.2±0.84*** 
*** Significant,p<0.001(with control). $$ significant,p<0.001, (with 
standard), ANOVA followed by Tukey-Kramer multiple comparison, N=6. 
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The C/B mass ratio after intracolonic administration of TNBS was 
significantly higher compared to the healthy control group (p<0.001). 
After oral administration of budesonide suspension and microspheres, 
the C/B ratio was decreased compared to the colitis control group. The 
decrease in C/B ratio is due to the anti-inflammatory activity of 
budesonide. Microspheres show better therapeutic effect than that of the 
suspension. This may be due to the release of drug from the chitosan 
polymer in the colonic region. Polymer doesn’t have any effect in 
controlling colitis.  Standard drug treated group reduces the severity of 
colitis but the effect observed is less than that of microspheres.  
The increased activity of microspheres may be due to the localised 
release of the steroidal drug. 
Clinical activity score and body mass change 
All rats treated with TNBS developed clinical symptoms such as loss 
of appetite, bloody diarrhoea and significant body mass loss 
(p<0.001). This could confirm the colitis model.  
Gross bleeding was observed in colitis control group, and polymer 
treated group. Pasty and semi-formed stools were seen in other groups.  
 
Table 2: Clinical activity score 
Groups Stool consistency Rectal bleeding Weight loss Clinical score 
Healthy control 0 0 0 0 
Colitis control 3.8±0.6 3.6±0.6 3.8±0.2 3.8 *** 
Budesonide. Suspension 2.2±1.2 2.4±0.6 3.0±0.8 2.5*** 
Budesonide microspheres 2.2±0.2 2.0±0.4 3.2±0.6 2.5***$$ 
Standard drug (5-ASA) 2.6±0.5 3.2±0.6 2.6±0.8 2.8*** 
Polymer suspension 3.8±0.4 3.6±0.4 3.8±0.2 3.8 *** 
*** Significant,p<0.001(with control). $$ significant,p<0.001, (with standard), ANOVA followed by Tukey-Kramer multiple comparisons, N=6 
 
Table 3: Body mass change (%) 
Groups  % change in body mass 
Healthy control +22.60±0.58 
Colitis control -25.67±0.63*** 
Budesonide suspension +3.10±0.36*** 
Budesonide microspheres +3.67±0.38*** 
Standard drug(5-ASA) -4.82±0.43*** 
Polymer suspension -24.77±0.68*** 
*Body mass change after 7 d treatment,-loss in weight,+increase in weight, *** Significant,p<0.001(with control), ANOVA followed by Tukey-Kramer 
multiple comparison, N=6 
 
On day 0, the body mass of rat was 178.0±0 6.8 g in the healthy 
control group (n=6) and 180±4.8 g in groups treated with TNBS 
(n=30), which shows no significant difference between them. The 
average mass gain in the healthy control group was 22.60±0.58%, 
but the rates in the colitis group suffered significant body mass loss 
of-25.67±0.63%. The results in table (3) shows that the polymer 
group and the colitis control group do not show a significant 
difference from each other. All other groups differ in the body mass 
changes from the colitis control group significantly (p<0.001). 
During the treatment period, the signs of colitis started to decrease 
in severity for all treated groups except polymer groups. Effects of 
budesonide microspheres and budesonide suspension are 
statistically significant with that of standard drug (p<0.001). Colitis 
can be controlled effectively using budesonide. 
Macroscopic damage score 
The colon in colitis control group was severely damaged, indicated 
by mucosal hyperaemia, haemorrhage, deep ulcers and necrosis. 
Daily treatment with budesonide microspheres reduces the damage 
and shows the significant result (P<0.01) as observed in table (4). 
Polymer treated group doesn’t have any effect on relieving the 
symptoms
 
Table 4: Data of macroscopic damage score in control and treatment groups after 7 d treatment 
Groups Macroscopic score 
Healthy control 0.0±0.0 
Colitis control  3.0±0.18*** 
Budesonide Suspension 2.4±0.30***$ 
Standard drug (5-ASA) 2.5±0.06***$ 
Budesonide microspheres  2.3±0.30***$ 
Polymer suspension 2.8±0.40*** 
*** significant, p<0.001, with Healthy control, $ significant, p<0.05, with Colitis control, ANOVA followed by Tukey-Kramer multiple comparison, N=6 
 
Determination of myeloperoxidase (MPO) enzyme activity 
Myeloperoxidase is an endogenous enzyme in mammalian 
granulocyte and plays an important role in the initiation and 
progression of acute and chronic inflammation. The activity of MPO, 
which is found in neutrophils and in small quantities in monocytes 
and macrophages can be used for evaluating the degree of 
inflammation in the intestine. Myeloperoxidase is soluble in 
hexadecyl trimethyl ammonium bromide and activity is measured 
with a dianisidine-hydrogen peroxide assay.  
Hexadecyl trimethyl ammonium bromide is a detergent that releases 
MPO from the primary granules of the neutrophil [21]. The MPO 
activity after the intra colonic administration of TNBS increased 
significantly compared with healthy control group (p<0.001) as 
observed in table (5). MPO activity decreased significantly after oral 
administration of budesonide suspension and microspheres 
(p<0.01). The effect is comparable with standard drug. On the other 
hand, no marked effect was observed after oral administration of 
polymer suspension. The result also confirmed the anti-
inflammatory activity of budesonide. 
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Table 5: Biochemical analysis of colon tissue homogenates for myeloperoxidase enzyme (MPO) activity 
Groups MPO unit/g of wet tissue 
Healthy Control 0.14±0.36 
Colitis control  0.52±0.42*** 
Budesonide Suspension 0.24±0.22*** 
Standard drug (5-ASA) 0.22±0.04** 
Budesonide microspheres  0.20±0.16* 
Polymer suspension 0.50±0.26*** 




The histopathological investigation was carried out on the excised 
colon and the fig. 1, 2, 3, 4 and 5 show microscopic images of the 
stained specimens. The findings are as follows:  
The tissue obtained from healthy control group showed intact colon 
with normal villi, normal glands and lamina propria fig. (1). 
 
 
Fig. 1: Normal colon 
 
Tissues excised from TNBS administered colitis group showed 
mucosal ulceration, mild distortion of glands, neutrophilic 




Fig. 2: TNBS induced ulcerative colon 
Tissues excised from microspheres treated group shows less of 
inflammation, more of goblet cells compared to colitis control group 
as observed in fig. (3). 
 
 
Fig. 3: Site showing healing of ulcer by administration of 
microspheres 
 
Blunted villi, distorted glands, increased inflammatory cells in 
lamina propria are seen in tissues treated with polymer group. 
Changes are similar to chronic ulcerative colitis as shown in fig. (4). 
 
 
Fig. 4: Polymer treated colon 
 
Fig. (5) Represents standard drug treated group shows slight 
blunting of villi, no distortion, the normal number of goblet cells and 
scanty inflammation. 
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Fig. 5: Standard drug treated colon 
 
In vivo targeting efficiency 
X-ray studies revealed that the microspheres remained in the 
stomach for the first 2h as shown in fig. (7). Microspheres get 
released from the capsule shell by dissolving the gelatin shell and 
distributed in the small intestine as observed in the fig. (8).  
Since the particles are small, and the amount of radio-opaque 
material is also less, the amount of microspheres visible by X-rays is 
also minimal. Microspheres are visible at 4th h in the small intestine 
as observed in fig.(8), and some are also seen in the X-ray image 
taken at the 8th h in the large intestinal region [22]. X-ray image at 
10th
 
 h indicates the presence of microspheres in the colonic region as 
seen in fig.(10). The observations were confirmed by a veterinary 
surgeon. It can be concluded that the formulation is able to target 
colonic region effectively. 
 
Fig. 6: X-ray image before drug administration 
 
Fig. 7: X-ray image 2 h after microspheres administration 
 
 
Fig. 8: X-ray image after 4 h 
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Fig. 9: X-ray image after 8 h 
 
 
Fig. 10: X-ray image after 10 h 
In vivo release study 
Analysis of blood samples did not show the presence of budesonide 
in detectable amount while fecal content analysis reveals the 
presence of the drug. HPLC analysis of budesonide pure drug sample 
shows two characteristic peaks representing epimer A and epimer B 
of budesonide in the chromatogram as observed in fig. (11). 
 
 
Fig. 11: HPLC analysis of pure budesonide sample 
 
Blood sample analysis after 2h of administration of the formulation 
is shown in the fig.(12). In this characteristic peaks are absent that 
indicate the absence of budesonide in the blood sample. 
 
 
Fig.12: HPLC analysis of blood sample following administration 
of budesonide microspheres (after 2h) 
 
HPLC analysis of blood samples after 4, 6, 8 and 24 h of 
administration of the formulation in the rabbit showed the absence 
of budesonide. Faecal content analysis indicated the presence of the 
drug. 
CONCLUSION 
The study showed that oral administration of budesonide 
microspheres exerted an affirmative impact on the colonic ulcer 
healing by decreasing the area of ulceration, reducing the mass of 
colon by improving the symptoms of colitis. MPO activity decreased 
significantly after oral administration of microspheres. 
Histopathological studies carried out also confirmed the result. 
Tissue excised from microspheres treated group shows less 
inflammation and more goblet cells than colitis control group. In vivo 
study conducted on rabbits proved that the drug was not present in 
a detectable amount in the blood sample collected at different time 
intervals after oral administration of the dosage form while faecal 
content analysis indicated the presence of the drug. The X-ray 
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studies revealed that the formulations are able to target the colon. 
With the permission of human ethical committee, detailed 
scintigraphic studies are needed to investigate its potential for 
clinical use. 
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